NMP22 is a tumor marker for bladder cancer. NMP22 is the abbreviated form of Nuclear Matrix Protein Number 22  It reflects the mitotic activity of cells.
It has been developed as a FDA and CE approved bladder cancer detection marker commercialized under the name of NMP22 bladercheck®. Results can be obtained within 30 minutes. This test is proposed for screening, diagnosis and surveillance of bladder cancer in conjunction with standard diagnostic procedures. Nonetheless there are no recommendation for its systematic use in clinical practice based on clinical guidelines either from the US (American Urological Association guidelines) or in Europe (European Association of Urology guidelines) since there are no level 1 evidence showing that the use of this test would have a significant impact on bladder cancer outcomes.
- Kumar A, Kumar R, Gupta NP (March 2006). "Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer". Jpn. J. Clin. Oncol. 36 (3): 172–5. doi:10.1093/jjco/hyi244. PMID 16520358.
- Moonen PM, Kiemeney LA, Witjes JA (December 2005). "Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer". Eur. Urol. 48 (6): 951–6; discussion 956. doi:10.1016/j.eururo.2005.09.002. PMID 16257108.
- Bassi P, De Marco V, De Lisa A, et al. (2005). "Non-invasive diagnostic tests for bladder cancer: a review of the literature". Urol. Int. 75 (3): 193–200. doi:10.1159/000087792. PMID 16215303.
|This biochemistry article is a stub. You can help Wikipedia by expanding it.|